MAY 12, 2016 6:00 AM PDT

The sequencing of 10,000 Human Genomes

Speaker
  • Head of Genomics, Human Longevity, Inc., Research Scientist, J Craig Venter Institute
    Biography
      Amalio Telenti is head of genomics at Human Longevity. He directs a team working on genetics (annotation of genome reports, pharmacogenetics) and genomics (reference genomes, analysis of non-coding genome regions, and data integration). Recently, he led the analysis of the first 10,000 genomes sequenced at HLI.

      A. Telenti trained in internal medicine and infectious diseases at the Mayo Clinic (Rochester, MN), and in microbiology and genetics at the University of Berne, Switzerland, at the Albert Einstein College of Medicine (Bronx, NY), and at the Ragon Institute of MGH, MIT and Harvard (Boston, MA). Between 2007 and 2014 he was professor and director of the Institute of Microbiology at the University of Lausanne, Switzerland. He has published extensively and received many national and international awards, including the prestigious Clo√ętta Award, one of the highest distinctions in medicine in Switzerland. In 2012, he was elected member of the Swiss Academy of Medical Sciences. He maintains academic affiliations with the J. Craig Venter Institute and with the Department of Medicine, University of California San Diego.

    Abstract

    Technological advances allow for the large scale sequencing of the whole human genome. Most studies have generated population-based information on human diversity using low to intermediate coverage of the genome (4x to 20x sequencing depth). The recent release of the Illumina HiseqX-Ten allows the sequencing of up to 160 genomes at 30x mean depth in 3 day cycles, at an average cost of $1,000 to $2,000 per genome. We evaluated the capabilities of this new technology by sequencing 10,545 human genomes at high depth. This allowed for the development of a reliable representation of human single nucleotide variation, the reporting of clinically relevant single nucleotide variants and the identification of additional non-reference and of putative human-like sequences.

    Learning objectives
    1.    Evaluating the impact of deep sequencing for the reporting on single genomes
    2.    Understanding the pace of discovery afforded by large scale sequencing of human genomes


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    FEB 19, 2020 11:00 AM PST
    C.E. CREDITS
    FEB 19, 2020 11:00 AM PST
    DATE: February 19, 2020TIME: 11:00am PST, 2:00pm EST...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    JUN 23, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    Loading Comments...
    Show Resources
    Attendees
    • See more